SV2009003420A - Nuevos compuestos ligandos del receptor de la adenosina a3 - Google Patents

Nuevos compuestos ligandos del receptor de la adenosina a3

Info

Publication number
SV2009003420A
SV2009003420A SV2009003420A SV2009003420A SV2009003420A SV 2009003420 A SV2009003420 A SV 2009003420A SV 2009003420 A SV2009003420 A SV 2009003420A SV 2009003420 A SV2009003420 A SV 2009003420A SV 2009003420 A SV2009003420 A SV 2009003420A
Authority
SV
El Salvador
Prior art keywords
compounds
general formula
solvatos
oxides
salts
Prior art date
Application number
SV2009003420A
Other languages
English (en)
Inventor
Edit Susan
Kinga Boer
Zoltan Kapui
Geza Timari
Sandor Batori
Zoltan Szlavik
Endre Mikus
Szeredi Hudit Vargane
Michel Finet
Tibor Szabo
Szabo Katalin Urban
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of SV2009003420A publication Critical patent/SV2009003420A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A LOS LIGANDOS DEL RECEPTOR DE ADENOSINA A3 DE FÓRMULA GENERAL (I): (VER FORMULA); DENTRO DE ELLOS LOS FAVORABLES A LOS ANTAGONISTAS, A SUS SALES, SOLVATOS, A/-ÓXIDOS E ISÓMEROS, A LAS COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN LOS COMPUESTOS DE FÓRMULA GENERAL (I), SUS SALES, SOLVATOS, N-ÓXIDOS E ISÓMEROS, AL USO DE LOS COMPUESTOS DE FÓRMULA GENERAL (I), SUS SALES, SOLVATOS, N-ÓXIDOS E ISÓMEROS, A LA PREPARACIÓN DE LOS COMPUESTOS DE FÓRMULA GENERAL (I), SUS SALES, SOLVATOS, N-ÓXIDOS E ISÓMEROS, ASÍ COMO A LOS NUEVOS INTERMEDIARIOS DE FÓRMULA GENERAL (II), (VI), (XI), (XII) Y (XV) Y A LA PREPARACIÓN DE ELLOS
SV2009003420A 2007-06-07 2009-11-24 Nuevos compuestos ligandos del receptor de la adenosina a3 SV2009003420A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0700395A HUP0700395A2 (en) 2007-06-07 2007-06-07 Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates

Publications (1)

Publication Number Publication Date
SV2009003420A true SV2009003420A (es) 2010-04-26

Family

ID=89987565

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2009003420A SV2009003420A (es) 2007-06-07 2009-11-24 Nuevos compuestos ligandos del receptor de la adenosina a3

Country Status (45)

Country Link
US (1) US8338411B2 (es)
EP (1) EP2167470B1 (es)
JP (1) JP5487100B2 (es)
KR (1) KR20100031610A (es)
CN (1) CN101679272B (es)
AR (1) AR066873A1 (es)
AT (1) ATE502016T1 (es)
AU (1) AU2008259534B2 (es)
BR (1) BRPI0812257A2 (es)
CA (1) CA2689612A1 (es)
CL (1) CL2008001648A1 (es)
CO (1) CO6270233A2 (es)
CR (1) CR11171A (es)
CY (1) CY1111644T1 (es)
DE (1) DE602008005589D1 (es)
DK (1) DK2167470T3 (es)
DO (1) DOP2009000276A (es)
EC (1) ECSP099783A (es)
ES (1) ES2363672T3 (es)
GT (1) GT200900301A (es)
HK (1) HK1138581A1 (es)
HN (1) HN2009003357A (es)
HR (1) HRP20110332T1 (es)
HU (1) HUP0700395A2 (es)
IL (1) IL202471A0 (es)
JO (1) JO2689B1 (es)
MA (1) MA31738B1 (es)
ME (1) ME00958B (es)
MX (1) MX2009013209A (es)
MY (1) MY148654A (es)
NI (1) NI200900210A (es)
NZ (1) NZ581186A (es)
PA (1) PA8782901A1 (es)
PE (1) PE20090325A1 (es)
PL (1) PL2167470T3 (es)
PT (1) PT2167470E (es)
RU (1) RU2489432C2 (es)
SI (1) SI2167470T1 (es)
SV (1) SV2009003420A (es)
TN (1) TN2009000482A1 (es)
TW (1) TWI424998B (es)
UA (1) UA99463C2 (es)
UY (1) UY31130A1 (es)
WO (1) WO2008149168A1 (es)
ZA (1) ZA200908280B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012000435A (es) 2009-07-08 2012-06-01 Dermira Canada Inc Analogos de acido 5-(tetradeciloxi)-2-furancarboxilico (tofa) utiles en el tratamiento de trastornos o afecciones dermatologicas.
FR3053968A1 (fr) * 2016-07-13 2018-01-19 Biomerieux Reactifs pour la protection reversible de molecules biologiques
CN109069502B (zh) * 2016-09-24 2021-08-06 山东亨利医药科技有限责任公司 含盐皮质激素受体拮抗剂的药物组合物及其用途
CN112384515A (zh) 2018-02-27 2021-02-19 因赛特公司 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
MX2020012376A (es) 2018-05-18 2021-03-09 Incyte Corp Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479759A (en) * 1974-11-23 1977-07-13 Lepetit Spa Heterocyclic fused derivatives of indole and quinoline
GR76063B (es) * 1981-04-03 1984-08-03 Roussel Uclaf
ZA836701B (en) * 1982-10-01 1984-10-31 Roussel Uclaf Imidazo(1,2-a)quinolines
GB0108475D0 (en) 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
RS95003A (en) * 2001-05-31 2007-02-05 Sanofi-Aventis, Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
HUP0105407A3 (en) * 2001-12-21 2004-04-28 Sanofi Aventis Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
WO2003053973A1 (de) 2001-12-21 2003-07-03 Jsw-Research Forschungslabor Gmbh Pyrazolyl-substituierte triazolochinoxaline
HUP0105406A3 (en) * 2001-12-21 2003-12-29 Sanofi Aventis Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
AU2004259127B2 (en) * 2003-07-31 2009-05-28 Sanofi-Aventis Aminoquinoline derivatives and their use as adenosine A3 ligands

Also Published As

Publication number Publication date
NI200900210A (es) 2010-07-15
HN2009003357A (es) 2013-08-12
CL2008001648A1 (es) 2008-10-10
AU2008259534A1 (en) 2008-12-11
US8338411B2 (en) 2012-12-25
ME00958B (me) 2012-06-20
ES2363672T3 (es) 2011-08-11
TW200914451A (en) 2009-04-01
NZ581186A (en) 2012-03-30
GT200900301A (es) 2010-04-22
JP5487100B2 (ja) 2014-05-07
EP2167470A1 (en) 2010-03-31
UA99463C2 (en) 2012-08-27
AU2008259534B2 (en) 2012-07-05
WO2008149168A8 (en) 2010-01-07
CN101679272B (zh) 2013-02-06
RU2489432C2 (ru) 2013-08-10
MY148654A (en) 2013-05-15
ZA200908280B (en) 2010-07-28
AR066873A1 (es) 2009-09-16
WO2008149168A1 (en) 2008-12-11
HUP0700395A2 (en) 2009-03-02
TWI424998B (zh) 2014-02-01
US20100216786A1 (en) 2010-08-26
PL2167470T3 (pl) 2011-08-31
CO6270233A2 (es) 2011-04-20
ATE502016T1 (de) 2011-04-15
DE602008005589D1 (de) 2011-04-28
MX2009013209A (es) 2010-04-09
HU0700395D0 (en) 2007-07-30
KR20100031610A (ko) 2010-03-23
EP2167470B1 (en) 2011-03-16
PE20090325A1 (es) 2009-04-17
ECSP099783A (es) 2010-01-29
PT2167470E (pt) 2011-05-16
CY1111644T1 (el) 2015-10-07
IL202471A0 (en) 2010-06-30
MA31738B1 (fr) 2010-10-01
HRP20110332T1 (hr) 2011-06-30
BRPI0812257A2 (pt) 2014-12-23
RU2009149518A (ru) 2011-07-20
UY31130A1 (es) 2009-01-30
CN101679272A (zh) 2010-03-24
DK2167470T3 (da) 2011-06-27
PA8782901A1 (es) 2009-01-23
SI2167470T1 (sl) 2011-06-30
CR11171A (es) 2010-04-21
HK1138581A1 (en) 2010-08-27
TN2009000482A1 (en) 2011-03-31
CA2689612A1 (en) 2008-12-11
DOP2009000276A (es) 2010-01-31
JO2689B1 (en) 2013-03-03
JP2010529100A (ja) 2010-08-26

Similar Documents

Publication Publication Date Title
SV2010003472A (es) Compuestos de pirazol
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
DOP2009000039A (es) COMPUESTOS DE PIRIDO (2,3-D) PIRIMIDINONA Y SU USO COMO INHIBIDORES DE P13-Ka
UY29798A1 (es) Derivados de carboxamida como antagonistas del receptor muscarínico
SV2010003580A (es) Agonistas novedosos de los receptores de glucocorticoides
DOP2011000361A (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cancer y otras enfermedades
UY32292A (es) Agonistas de s1p1 y métodos de preparación y uso
UY31367A1 (es) Derivados de nicotinamida, su preparacion y su aplicacion en terapeutica
CR20120264A (es) Compuestos
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
SV2009003420A (es) Nuevos compuestos ligandos del receptor de la adenosina a3
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
UY31048A1 (es) Nuevos compuestos de pirimidina y usos de los mismos
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
CR20130671A (es) Antagonistas de trpv4
UY32055A (es) Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones.
NI201100015A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico.
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
ECSP067028A (es) Profármacos de esteroides con acción androgénica
PA8805301A1 (es) Derivados de pirazol como inhibidores de 5-lo
CR9595A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona
UY31338A1 (es) Compuestos novedosos activos como antagonistas de receptores muscarinicos
CU23564A3 (es) Derivados de carboxamida como antagonistas del receptor muscarínico
CU20110003A7 (es) Compuestos novedosos activos como antagonistas de receptor muscarínico